264 related articles for article (PubMed ID: 23820269)
1. Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses.
Chen HW; Cheng JX; Liu MT; King K; Peng JY; Zhang XQ; Wang CH; Shresta S; Schooley RT; Liu YT
Antiviral Res; 2013 Sep; 99(3):371-82. PubMed ID: 23820269
[TBL] [Abstract][Full Text] [Related]
2. Antiviral efficacy of nanoparticulate vacuolar ATPase inhibitors against influenza virus infection.
Hu CJ; Chen YT; Fang ZS; Chang WS; Chen HW
Int J Nanomedicine; 2018; 13():8579-8593. PubMed ID: 30587980
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticulate vacuolar ATPase blocker exhibits potent host-targeted antiviral activity against feline coronavirus.
Hu CJ; Chang WS; Fang ZS; Chen YT; Wang WL; Tsai HH; Chueh LL; Takano T; Hohdatsu T; Chen HW
Sci Rep; 2017 Oct; 7(1):13043. PubMed ID: 29026122
[TBL] [Abstract][Full Text] [Related]
4. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption.
Sørensen MG; Henriksen K; Neutzsky-Wulff AV; Dziegiel MH; Karsdal MA
J Bone Miner Res; 2007 Oct; 22(10):1640-8. PubMed ID: 17576165
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic Prioritization of Diphyllin Derivatives That Block Filoviral Cell Entry by Vacuolar (H
Lindstrom A; Anantpadma M; Baker L; Raghavendra NM; Davey R; Davisson VJ
ChemMedChem; 2018 Dec; 13(24):2664-2676. PubMed ID: 30335906
[TBL] [Abstract][Full Text] [Related]
6. Diphyllin Shows a Broad-Spectrum Antiviral Activity against Multiple Medically Important Enveloped RNA and DNA Viruses.
Štefánik M; Bhosale DS; Haviernik J; Straková P; Fojtíková M; Dufková L; Huvarová I; Salát J; Bartáček J; Svoboda J; Sedlák M; Růžek D; Miller AD; Eyer L
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215947
[TBL] [Abstract][Full Text] [Related]
7. The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections.
Müller KH; Kainov DE; El Bakkouri K; Saelens X; De Brabander JK; Kittel C; Samm E; Muller CP
Br J Pharmacol; 2011 Sep; 164(2):344-57. PubMed ID: 21418188
[TBL] [Abstract][Full Text] [Related]
8. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.
Nguyen JT; Hoopes JD; Le MH; Smee DF; Patick AK; Faix DJ; Blair PJ; de Jong MD; Prichard MN; Went GT
PLoS One; 2010 Feb; 5(2):e9332. PubMed ID: 20179772
[TBL] [Abstract][Full Text] [Related]
9. Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function.
Jang Y; Shin JS; Yoon YS; Go YY; Lee HW; Kwon OS; Park S; Park MS; Kim M
J Virol; 2018 Dec; 92(24):. PubMed ID: 30282713
[TBL] [Abstract][Full Text] [Related]
10. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.
Nguyen JT; Hoopes JD; Smee DF; Prichard MN; Driebe EM; Engelthaler DM; Le MH; Keim PS; Spence RP; Went GT
Antimicrob Agents Chemother; 2009 Oct; 53(10):4115-26. PubMed ID: 19620324
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors targeting the influenza virus hemagglutinin.
Li F; Ma C; Wang J
Curr Med Chem; 2015; 22(11):1361-82. PubMed ID: 25723505
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses.
Zhao X; Li R; Zhou Y; Xiao M; Ma C; Yang Z; Zeng S; Du Q; Yang C; Jiang H; Hu Y; Wang K; Mok CKP; Sun P; Dong J; Cui W; Wang J; Tu Y; Yang Z; Hu W
J Med Chem; 2018 Jun; 61(12):5187-5198. PubMed ID: 29799746
[TBL] [Abstract][Full Text] [Related]
13. A Drosophila model for genetic analysis of influenza viral/host interactions.
Adamson AL; Chohan K; Swenson J; LaJeunesse D
Genetics; 2011 Oct; 189(2):495-506. PubMed ID: 21775472
[TBL] [Abstract][Full Text] [Related]
14. [Drug-resistant influenza viruses: an overview].
Hatakeyama S
Nihon Rinsho; 2010 Sep; 68(9):1671-8. PubMed ID: 20845746
[TBL] [Abstract][Full Text] [Related]
15. Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.
McKimm-Breschkin JL; Fry AM
Antiviral Res; 2016 May; 129():21-38. PubMed ID: 26872862
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of influenza virus replication by plant-derived isoquercetin.
Kim Y; Narayanan S; Chang KO
Antiviral Res; 2010 Nov; 88(2):227-35. PubMed ID: 20826184
[TBL] [Abstract][Full Text] [Related]
17. Effects of diphyllin as a novel V-ATPase inhibitor on gastric adenocarcinoma.
Shen W; Zou X; Chen M; Liu P; Shen Y; Huang S; Guo H; Zhang L
Eur J Pharmacol; 2011 Sep; 667(1-3):330-8. PubMed ID: 21645513
[TBL] [Abstract][Full Text] [Related]
18. An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.
Hu Y; Musharrafieh R; Ma C; Zhang J; Smee DF; DeGrado WF; Wang J
Antiviral Res; 2017 Apr; 140():45-54. PubMed ID: 28087313
[TBL] [Abstract][Full Text] [Related]
19. Herbal Medicines with Antiviral Activity Against the Influenza Virus, a Systematic Review.
Lee JY; Abundo MEC; Lee CW
Am J Chin Med; 2018; 46(8):1663-1700. PubMed ID: 30612461
[TBL] [Abstract][Full Text] [Related]
20. Influenza virus neuraminidase inhibitors.
Gubareva LV; Kaiser L; Hayden FG
Lancet; 2000 Mar; 355(9206):827-35. PubMed ID: 10711940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
